Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is Terns Pharmaceuticals. Presenting on behalf of the company is President and Head of R&D, Erin Quirk.
(Conference Instructions) So with that, Erin, thanks for joining us.
Great. Eric, thanks so much for the introduction. And thanks to you and the entire JPMorgan team for the opportunity to be at the conference and present today. It's always great to be at JPMorgan, and we really appreciate the support and invitation.
So I'll give you an overview of Terns today and the really exciting outlook we have for 2024. As always, I'd invite you to go to our website to look at disclaimers regarding forward-looking statements.
So Terns is a biotech company. We're developing small molecule medicines with clinically validated mechanisms of action to address important needs focused currently on oncology and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
